| Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. | |
| | |
MedLine Citation:
|
PMID: 21386634 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Neuroendocrine tumors of pancreas (PNET) are very rare, consisting of heterogeneous histological subtypes with a variable natural history and different clinical manifestations. Although the vast majority of these neoplasms are sporadic, it is possible to be part of a genetic syndrome such as multiple endocrine neoplasia 1 (MEN-1) or tuberous sclerosis (TSC). When systemic treatment is required the options are limited and management strategy is generally based on experts' consensus or clinical experience. The prognosis is usually better than in pancreatic adenocarcinoma, though poorly differentiated PNET behave aggressively and survival is shortened. Since last year, there has been a significant advance in the management of PNET, after reported data confirmed the efficacy of everolimus, an mTOR inhibitor, in patients with advanced disease. At the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium, updated results of the phase III trial (RADIANT-3) regarding the efficacy of everolimus in PNET (Abstract #158) were reported, along with the results of a subgroup analysis of the Japanese patients enrolled in this study (Abstract #289). Another agent with promising activity in PNET which will be discussed in this review is sunitinib, a biological agent with multikinase inhibitor properties (Abstract #244). |
| | |
Authors:
|
Alexios S Strimpakos; Konstantinos N Syrigos; Muhammad Wasif Saif |
Related Documents
:
|
19856054 - The contribution of limited-resource countries to the american society of clinical onco... 19763704 - Summary of proceedings at the 43rd annual pancreas club meeting. 7798604 - Lesbian identity and the politics of representation in betty parsons's gallery. 19919234 - Contemporary orthodontic education. 20936334 - The potentially biasing effects of voir dire in juvenile waiver cases. 12172524 - Clinical ethics in rehabilitation medicine: core objectives and algorithm for resident ... |
Publication Detail:
|
Type: Congresses Date: 2011-03-09 |
Journal Detail:
|
Title: JOP : Journal of the pancreas Volume: 12 ISSN: 1590-8577 ISO Abbreviation: JOP Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-03-09 Completed Date: 2011-08-09 Revised Date: 2011-10-18 |
Medline Journal Info:
|
Nlm Unique ID: 101091810 Medline TA: JOP Country: Italy |
Other Details:
|
Languages: eng Pagination: 117-9 Citation Subset: IM |
Affiliation:
|
Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital. Athens, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use Clinical Trials, Phase III as Topic Humans Immunosuppressive Agents / therapeutic use Indoles / therapeutic use Neuroendocrine Tumors / drug therapy*, pathology Pancreatic Neoplasms / drug therapy*, pathology Pyrroles / therapeutic use Sirolimus / analogs & derivatives*, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Immunosuppressive Agents; 0/Indoles; 0/Pyrroles; 0/sunitinib; 159351-69-6/everolimus; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2...
Next Document: Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers...